Biopact on Equifund CFP

PATENTED TECHNOLOGY THAT MAKES FIGHTING DISEASE SIMPLER, FASTER AND CHEAPER.

Raise to date: $45,585

Reporting Date: 03/29/2020

Key Stats

Minimum Raise

$20,000

Maximum Raise

$1,070,000

Likelihood of Max Unlikely
Start Date

02/26/2020

Stop Date

06/30/2020

Days Remaining

91

Security Type

Common Stock

Investment Minimum

$465

Deal Type

Deal to Watch


Investment Summary

Status

Active

# of Investors

36

% of Minimum Raised

228%

% of Maximum Raised

4%

Dollars Per Day to Reach Max

$11,257

DPD* Committed

$1,425

DPD* Category

$0

DPD* All Companies

$961

Kingscrowd Momentum

$45,585

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Biopact Cellular Transport, with a valuation of $30 million, is raising funds on Equifund Crowd Funding Platform. The company has a unique patented intracellular delivery technology that transports gene-editing technologies to cells effectively, safely, and affordably. The delivery mechanism of Biopact Cellular Transport will help reduce the cost and increase the effectiveness of therapies like CRISPR, TALEN, and CAR-T. Biopact Cellular Transport was founded by Kurt Swogger and is led by Randy Kinsel as the President. The current crowdfunding round of the company has a minimum target of $20,000 and a maximum target of $1,070,000. Biopact Cellular Transport’s MGMR technology is protected by 77 patents worldwide and has the potential to revolutionize cellular medicines.

INVEST NOW